Petrini P
Department of Paediatrics, Karolinska Hospital, Stockholm, Sweden.
Haemophilia. 2001 Jan;7(1):99-102. doi: 10.1046/j.1365-2516.2001.00471.x.
In order to prevent arthropathy, prophylaxis has to start at a young age before recurrent joint bleedings have taken place. The use of central venous lines has facilitated an early beginning to treatment, but due to side-effects, most European paediatricians prefer peripheral injections whenever possible. By starting primary prophylaxis at the age of 1--2 years with one injection weekly, the need for surgical implants may be reduced. In this study, only four of 34 boys born 1988--98 with severe haemophilia A or B needed a Port-a-Cath for primary prophylaxis. Trough levels were measured in these patients and 79% showed a trough level < 1%, while 21% reached a level > 1%. Despite this, joint bleedings during 1998 were rare in both groups [0--4] and 59% of the boys with trough levels < 1% did not report any haemartroses during that year. Mean annual joint bleedings were the same in both groups [0.70, 0.71]. The lowest effective level of factors VIII and IX must be determined individually for each patient on primary or secondary prophylaxis.
为预防关节病,必须在反复关节出血发生之前的幼年时期就开始预防。中心静脉置管的使用有助于早期开始治疗,但由于存在副作用,大多数欧洲儿科医生尽可能选择外周注射。通过在1至2岁时开始每周一次注射进行初级预防,可减少手术植入的需求。在本研究中,1988年至1998年出生的34名患有严重甲型或乙型血友病的男孩中,只有4名需要植入输液港进行初级预防。对这些患者进行谷浓度测量,79%的患者谷浓度<1%,而21%的患者谷浓度>1%。尽管如此,1998年两组患者的关节出血都很少见[0至4次],谷浓度<1%的男孩中有59%在该年未报告任何关节积血。两组的年均关节出血次数相同[0.70,0.71]。对于接受初级或二级预防的每位患者,必须单独确定凝血因子VIII和IX的最低有效水平。